VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer
10 sept. 2020 09h25 HE
|
VBL Therapeutics
Study to investigate for the first time a combination of VB-111 with the checkpoint inhibitor, nivolumab. TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT)...
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
08 sept. 2020 08h00 HE
|
VBL Therapeutics
Alignment with FDA on the path forward for the development of VB-601 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion...
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
13 août 2020 07h00 HE
|
VBL Therapeutics
●Positive data from the first interim analysis in the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer were presented at ASCO20; response rate in the VB-111 treatment arm was 58%...
VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
12 août 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned...
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
03 août 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
22 juin 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced...
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
04 juin 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for...
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
01 juin 2020 07h00 HE
|
VBL Therapeutics
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10%...
VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
18 mai 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that new data suggesting the potential of its proprietary bi-specific antibodies for...
VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update
14 mai 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. ...